Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.41 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.41 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.41 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018544 | 1.00 | HTT (0.42) | HTTGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15760884 | 0.81 | GUCY1B2 (0.40) | HTTGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15760882 | 0.81 | GUCY1B2 (0.40) | HTTGUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL20587889 | 0.77 | ACACB (0.43) | HTTMTNR1AMTNR1BACACBACACA | |
| SCHEMBL1549219 | 0.75 | LMNA (0.39) | L3MBTL1 | |
| SCHEMBL7723692 | 0.75 | ALDH1A1 (0.46) | HTTMTNR1AMTNR1BACACBACACA | |
| SCHEMBL10711904 | 0.74 | GABRA1 (0.50) | — | |
| SCHEMBL19658634 | 0.74 | L3MBTL1 (0.50) | HTTACACBACACAL3MBTL1 | |
| SCHEMBL28974132 | 0.74 | HTT (0.66) | HTTMTNR1AMTNR1BACACBACACA | |
| SCHEMBL17018471 | 0.74 | HTT (0.66) | HTTMTNR1AMTNR1BACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | HTT 4358/4885GUCY1B2 26/4885GUCY1A2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.